Breaking News Instant updates and real-time market news.

MYL

Mylan

$35.94

-0.9 (-2.44%)

10:40
10/10/16
10/10
10:40
10/10/16
10:40

Mylan rises after signing EpiPen settlement with DOJ

Mylan (MYL) shares are rallying after the drugmaker agreed to a $465M settlement over charges that it overcharged the government for its EpiPen products. In conjunction with the settlement, Mylan cut its guidance for the year. SETTLEMENT DETAILS: Mylan announced on Friday that it had reached a $465M settlement with the Department of Justice and other government agencies over questions on whether the company had overcharged Medicaid for the treatment by improperly classifying it as a generic drug. Mylan has been under intense scrutiny for raising the price of EpiPen to more than $600 for a pack of two from about $100 since it acquired the allergy treatment in 2007. In a statement, Mylan said the settlement did not imply any admission of wrongdoing. It also said the settlement had not been finalized, and that it expected to enter into a corporate integrity agreement with the Office of the Inspector General for the Department of Health and Human Services. "This agreement is another important step in Mylan's efforts to move forward and bring resolution to all EpiPen Auto-Injector related matters" CEO Heather Bresch stated, adding that the agreement is "in addition to the significant steps Mylan has taken in relation to EpiPen Auto-Injector over the past several weeks, including the unprecedented, pending launch of a generic version of EpiPen Auto-Injector and expansion of our patient access programs for this product." LOWERED GUIDANCE: As a result of the previously announced changes in EpiPen Auto-Injector access programs and the upcoming launch of the generic to EpiPen Auto-Injector, Mylan on Friday cut its fiscal 2016 adjusted earnings per share view to $4.70-$4.90 from $4.85-$5.15, below analysts' estimates at the time of $4.95. Mylan will take a pre-tax charge of approximately $465M in the third quarter as a result of the DOJ settlement. Looking ahead, Mylan backed its adjusted EPS target for fiscal 2018 of "at least" $6.00. ANALYSTS MOSTLY 'POSITIVE' ON SETTLEMENT, GUIDANCE: JPMorgan analyst Chris Schott said in a note to clients that he views the DOJ settlement and the updated 2016 guidance as a "positive." He said that the news "removes litigation overhang at a reasonable cost" and highlights the diversification of the base business and inexpensive valuation of the stock. Raymond James analyst Elliot Wilber agreed, and upgraded Mylan to Strong Buy from Market Perform, explaining that the DOJ settlement eliminates a significant overhang on shares enabling the focus to be on Mylan's fundamentals. Wilber now sees favorable risk/reward scenarios even in a more tempered earnings growth environment. UBS analyst Marc Goodman said he remains constructive on Mylan despite the controversy surrounding its corporate governance. Goodman, who reiterated a Buy rating but lowered his price target to $60 from $66 on Mylan shares, said the company's updated guidance was better than feared. WELLS' MARIS MORE CAUTIOUS: However, Wells Fargo analyst David Maris said questions remain after the settlement and updated 2016 guidance. Maris disagreed with investors that think the settlement puts the EpiPen pricing issue largely behind the company, and contended that the DOJ deal only addresses the Centers for Medicare and Medicaid Services portion of the issue, and does nothing to answer the original issue of EpiPen pricing and consumers. Maris keeps a Market Perform rating on Mylan shares. PRICE ACTION: Mylan is up over 8% to $38.92 in morning trading, though shares are still down over 32% year-to-date.

  • 09

    Nov

  • 28

    Mar

MYL Mylan
$35.94

-0.9 (-2.44%)

10/10/16
RAJA
10/10/16
UPGRADE
Target $57
RAJA
Strong Buy
Mylan upgraded to Strong Buy on EpiPen settlement at Raymond James
As previously reported, Raymond James upgraded Mylan two notches to Strong Buy from Market Perform and established a $57 price target. Analyst Elliot WIlbur said the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. With depressed absolute and relative valuation levels, Wilber sees favorable risk/reward scenarios even in a more tempered earnings growth environment.
10/10/16
JPMS
10/10/16
NO CHANGE
Target $52
JPMS
Overweight
Mylan settlement, updated guidance a positive, says JPMorgan
JPMorgan analyst Chris Schott views Mylan's $465M settlement with the Department of Justice relating to the potential misclassification of Epipen in the Medicaid Drug Rebate Program as well as its updated 2016 guidance as a positive. The news "removes litigation overhang at a reasonable cost and highlights the diversification of the base business and inexpensive valuation," Schott tells investors in a research note. He keeps an Overweight rating on Mylan with a $52 price target.
10/10/16
WELS
10/10/16
NO CHANGE
WELS
Mylan settlement does not end EpiPen issue, says Wells Fargo
In a research note titled "Forget After Hrs. Quarterbacking - It is Not Back to Normal," Wells Fargo analyst David Maris says Mylan questions still remain after the company's lowered 2016 outlook and $465M Department of Justice settlement. One of Mylan's earnings levers, EpiPen pricing, is now off the table going forward, Maris tells investors in a research note. The analyst disagrees with investors that think the settlement puts the EpiPen pricing issue largely behind the company. The deal with the DOJ addresses only the Centers for Medicare and Medicaid Services portion of the issue, it does nothing to answer the original issue of EpiPen pricing and consumers, Maris contends. He points out that Mylan also disclosed in Friday's regulatory filing, but not in its press release, an SEC investigation by the Division of Enforcement. Maris says he's "not too excited" and doesn't gauge how good the news is by the after-hours share rally of 10%. He believes Mylan is "not back to normal" and keeps a Market Perform rating on the stock with a $43-$45 price target range. The shares are up 12% in pre-market trading to $40.35. Raymond James this morning upgraded Mylan to Strong Buy.
10/10/16
10/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Strong Buy from Market Perform at Raymond James with Elliot WIlbur saying the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. 2. Under Armour (UA) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying "noise" from the Sports Authority's bankruptcy is fading while distribution expansion could lead to sales re-acceleration over the next 12-18 months. 3. Deere (DE) and AGCO (AGCO) were upgraded to Outperform from Market Perform at Wells Fargo. 4. Dow Chemical (DOW) upgraded to Buy from Neutral at UBS with analyst John Roberts saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." 5. Exelixis (EXEL) upgraded to Overweight from Neutral at Piper Jaffray with analyst Edward Tenthoff saying the data are "good enough" to file a supplemental new drug application and could drive off-label front-line RCC use. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

KPTI

Karyopharm

$9.96

0.46 (4.84%)

06:32
06/23/17
06/23
06:32
06/23/17
06:32
Hot Stocks
Karyopharm reports updated Phase 2b SADAL data for selinexor »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

DFIN

Donnelley Financial Solutions

$21.66

-0.41 (-1.86%)

06:27
06/23/17
06/23
06:27
06/23/17
06:27
Initiation
Donnelley Financial Solutions initiated  »

Donnelley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$57.64

-0.41 (-0.71%)

06:24
06/23/17
06/23
06:24
06/23/17
06:24
Upgrade
Prologis rating change  »

Prologis upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRE

Duke Realty

$28.28

-0.22 (-0.77%)

06:24
06/23/17
06/23
06:24
06/23/17
06:24
Downgrade
Duke Realty rating change  »

Duke Realty downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,001.30

-0.93 (-0.09%)

, WFM

Whole Foods

$43.20

-0.06 (-0.14%)

06:23
06/23/17
06/23
06:23
06/23/17
06:23
Periodicals
Some believe Whole Foods would give Amazon 'unfair advantage,' Reuters says »

Antitrust experts believe…

AMZN

Amazon.com

$1,001.30

-0.93 (-0.09%)

WFM

Whole Foods

$43.20

-0.06 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

06:21
06/23/17
06/23
06:21
06/23/17
06:21
Technical Analysis
Technical View: Bed Bath & Beyond tumbles after earnings miss expectations »

The company reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

NAP

Navios Maritime Midstream

$9.88

0.13 (1.33%)

06:19
06/23/17
06/23
06:19
06/23/17
06:19
Downgrade
Navios Maritime Midstream rating change  »

Navios Maritime Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

, GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

06:19
06/23/17
06/23
06:19
06/23/17
06:19
Periodicals
Waymo hires former Tesla engineer to lead hardware team, Bloomberg says »

Alphabet's (GOOG,…

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

TSLA

Tesla

$382.61

6.21 (1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

  • 02

    Oct

TSN

Tyson Foods

$61.72

0.34 (0.55%)

06:16
06/23/17
06/23
06:16
06/23/17
06:16
Hot Stocks
Tyson Foods to invest $49M to expand Macon, GA distribution center »

Tyson Foods, Inc. is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$32.66

-0.5 (-1.51%)

06:15
06/23/17
06/23
06:15
06/23/17
06:15
Downgrade
Hain Celestial rating change  »

Hain Celestial downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

BA

Boeing

$199.44

0.27 (0.14%)

, EADSY

Airbus

$20.80

-0.07 (-0.34%)

06:14
06/23/17
06/23
06:14
06/23/17
06:14
Periodicals
Boeing announces layoffs at 787 Dreamliner campus, Post and Courier says »

Boeing (BA) is cutting…

BA

Boeing

$199.44

0.27 (0.14%)

EADSY

Airbus

$20.80

-0.07 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.40

-0.51 (-0.33%)

, MSFT

Microsoft

$70.26

-0.01 (-0.01%)

06:12
06/23/17
06/23
06:12
06/23/17
06:12
Periodicals
LinkedIn CEO: Sandberg seems 'quite happy' at Facebook, NY Post reports »

Jeff Weiner, the CEO of…

FB

Facebook

$153.40

-0.51 (-0.33%)

MSFT

Microsoft

$70.26

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

  • 20

    Jul

SKT

Tanger Factory

$25.70

0.48 (1.90%)

06:11
06/23/17
06/23
06:11
06/23/17
06:11
Downgrade
Tanger Factory rating change  »

Tanger Factory downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$20.80

-0.07 (-0.34%)

06:09
06/23/17
06/23
06:09
06/23/17
06:09
Periodicals
Airbus' sales chief Leahy may retire before Dubai Airshow, Reuters reports »

John Leahy, Airbus'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,001.30

-0.93 (-0.09%)

, TWTR

Twitter

$18.15

0.37 (2.08%)

06:07
06/23/17
06/23
06:07
06/23/17
06:07
Periodicals
Amazon wants to sell Thurs. Night Football ad deals for $2.8M each, Reuters says »

Amazon (AMZN) wants to…

AMZN

Amazon.com

$1,001.30

-0.93 (-0.09%)

TWTR

Twitter

$18.15

0.37 (2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

F

Ford

$11.13

0.09 (0.82%)

06:05
06/23/17
06/23
06:05
06/23/17
06:05
Periodicals
Ford recalling nearly 16,000 cars in South Africa due to fire risk, Reuters says »

Ford is recalling almost…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

ENOC

EnerNOC

$7.65

2.25 (41.67%)

06:05
06/23/17
06/23
06:05
06/23/17
06:05
Downgrade
EnerNOC rating change  »

EnerNOC downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$154.40

0.61 (0.40%)

06:05
06/23/17
06/23
06:05
06/23/17
06:05
Hot Stocks
IBM achieves climate protection goals four years early »

IBM announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIVHY

Vivendi

$22.76

-0.105 (-0.46%)

06:04
06/23/17
06/23
06:04
06/23/17
06:04
Upgrade
Vivendi rating change  »

Vivendi upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$103.84

0.37 (0.36%)

06:04
06/23/17
06/23
06:04
06/23/17
06:04
Downgrade
Caterpillar rating change  »

Caterpillar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$104.22

-0.58 (-0.55%)

, GOOG

Alphabet

$957.09

-2.36 (-0.25%)

05:59
06/23/17
06/23
05:59
06/23/17
05:59
Periodicals
Spotify names Staggs, Warrior to board; Parker leaves board, TechCrunch says »

Spotify has appointed…

DIS

Disney

$104.22

-0.58 (-0.55%)

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

CSCO

Cisco

$31.85

0.01 (0.03%)

P

Pandora

$7.80

0.29 (3.86%)

AMZN

Amazon.com

$1,001.30

-0.93 (-0.09%)

AAPL

Apple

$145.63

-0.24 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 12

    Jul

  • 19

    Jul

  • 08

    Aug

  • 16

    Aug

SPX

S&P 500

05:55
06/23/17
06/23
05:55
06/23/17
05:55
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$86.34

3.78 (4.58%)

05:52
06/23/17
06/23
05:52
06/23/17
05:52
Hot Stocks
Novartis Kisqali receives CHMP opinion as first-line treatment for HR+/HER2- »

Novartis announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 12

    Jul

GDX

Market Vector Gold Miners

$22.36

0.25 (1.13%)

05:51
06/23/17
06/23
05:51
06/23/17
05:51
Technical Analysis
Market Vector Gold Miners: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$118.92

0.4 (0.34%)

05:50
06/23/17
06/23
05:50
06/23/17
05:50
Technical Analysis
SPDR Gold Trust: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.